Evidence map›Paper›PMID 42077794›Full record

ArticleJournal of health economics and outcomes research2026

Systematic Literature Reviews of Health-State Utility Values, Costs, and Healthcare Resource Use in Duchenne Muscular Dystrophy.

Chui-Ying Yip, Eric N Kemadjou, Daisy Stewart, Hannah Shapiro, Tom Macmillan

Abstract read
In one paragraph

Article in Journal of health economics and outcomes research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Chui-Ying YipF. Hoffmann-La Roche Ltd, Basel, Switzerland.
Eric N KemadjouF. Hoffmann-La Roche Ltd, Basel, Switzerland.
Daisy StewartSource Health Economics, London, UK.
Hannah ShapiroSource Health Economics, London, UK.
Tom MacmillanSource Health Economics, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Duchenne muscular dystrophy (DMD) is a rare, X-linked inherited disorder starting in early childhood, characterized by progressive muscle loss and weakness, causing disability, loss of ambulation, and cardiopulmonary failure. Economic modeling is required to assess cost-effectiveness of new DMD therapies, but there are challenges from limitations and variations in currently available data. Objective: To assess the burden of DMD on patients, caregivers and healthcare systems, identifying inputs for cost-effectiveness models to inform economic assessments. Methods: Two systematic literature reviews (SLRs) were conducted. One SLR was performed to identify health state utility values (HSUV, original date 2019 with a 2023 update) and another to identify and cost data (original date 2023). Both SLRs were updated in 2024. Databases searched included Embase, MEDLINE, Centre for Reviews and Dissemination and EconLit, with additional hand-searching. PRISMA guidelines were followed. For each SLR, title/abstract and full-text screening were performed by two independent reviewers before data extraction. Validated quality assessment tools were used. Results: Across both SLRs, the burden increased as DMD progressed from early to late stages, indicated by decreasing HSUVs and increasing healthcare resource use and costs. The results highlighted large increases in burdens between early nonambulatory and late nonambulatory DMD in studies using the typical 4-state progression model. Recent publications using an 8-stage natural history model reported gradual increases in burden. There was heterogeneity between studies and a lack of long-term data in both SLRs. Discussion: The results highlighted the complex nature of progressive DMD, with heterogeneity and lack of long-term data across the studies. The findings suggest that HUI-3 may be the preferred tool for HSUV measurement in DMD, and the 8-stage natural history model may be preferable to typical 4-state models of DMD progression, to account for the observed heterogeneity and non-linear progression of this rare disease. Conclusions: These data indicate that the burden on patients, caregivers, and healthcare systems increases as DMD progresses. A wide range of inputs for economic modeling were identified, including insights into the way that the stages of DMD should be modeled to accurately reflect progression.

Indexed as

burdencostDuchenne muscular dystrophyeconomicsystematic reviewutilities

Identifiers

PMID42077794
PMCPMC13131909

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.